If times are tough, it may be tempting to scale back on finding the next HIV
treatment or smartphone
breakthrough, forgetting that, if successful, those things could
produce obscene, outsized profits.
In its first clinical trial, a
breakthrough antibody therapy
produced at least partial remissions in a third of patients with multiple myeloma who had exhausted multiple prior
treatments, investigators at Dana - Farber Cancer Institute and other organizations report today online in the New England Journal of Medicine.